333 related articles for article (PubMed ID: 23817193)
1. Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis.
Guckenberger M; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N
J Thorac Oncol; 2013 Aug; 8(8):1050-8. PubMed ID: 23817193
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
3. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system.
Katoh N; Soda I; Tamamura H; Takahashi S; Uchinami Y; Ishiyama H; Ota K; Inoue T; Onimaru R; Shibuya K; Hayakawa K; Shirato H
Radiat Oncol; 2017 Jan; 12(1):3. PubMed ID: 28057036
[TBL] [Abstract][Full Text] [Related]
5. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.
Guckenberger M; Klement RJ; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N; Flentje M
Radiother Oncol; 2013 Oct; 109(1):13-20. PubMed ID: 24183066
[TBL] [Abstract][Full Text] [Related]
6. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer.
Grills IS; Mangona VS; Welsh R; Chmielewski G; McInerney E; Martin S; Wloch J; Ye H; Kestin LL
J Clin Oncol; 2010 Feb; 28(6):928-35. PubMed ID: 20065181
[TBL] [Abstract][Full Text] [Related]
7. Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer.
Hamaji M; Chen F; Matsuo Y; Kawaguchi A; Morita S; Ueki N; Sonobe M; Nagata Y; Hiraoka M; Date H
Ann Thorac Surg; 2015 Apr; 99(4):1122-9. PubMed ID: 25661580
[TBL] [Abstract][Full Text] [Related]
8. Patterns of failure after stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer.
Robinson CG; DeWees TA; El Naqa IM; Creach KM; Olsen JR; Crabtree TD; Meyers BF; Puri V; Bell JM; Parikh PJ; Bradley JD
J Thorac Oncol; 2013 Feb; 8(2):192-201. PubMed ID: 23287852
[TBL] [Abstract][Full Text] [Related]
9. 30 Gy or 34 Gy? Comparing 2 single-fraction SBRT dose schedules for stage I medically inoperable non-small cell lung cancer.
Videtic GM; Stephans KL; Woody NM; Reddy CA; Zhuang T; Magnelli A; Djemil T
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):203-8. PubMed ID: 25015198
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates.
Jeppesen SS; Schytte T; Jensen HR; Brink C; Hansen O
Acta Oncol; 2013 Oct; 52(7):1552-8. PubMed ID: 23902274
[TBL] [Abstract][Full Text] [Related]
12. [Outcome of three-dimensional conformal radiotherapy for early stage non-small cell lung cancer patients who met or not inclusion criteria for stereotactic-body radiation therapy].
Kołodziejczyk M; Kępka L; Tyc-Szczepaniak D; Wierzchowski M
Pneumonol Alergol Pol; 2011; 79(5):326-36. PubMed ID: 21861256
[TBL] [Abstract][Full Text] [Related]
13. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation.
Guckenberger M; Wulf J; Mueller G; Krieger T; Baier K; Gabor M; Richter A; Wilbert J; Flentje M
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):47-54. PubMed ID: 18977095
[TBL] [Abstract][Full Text] [Related]
14. Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis.
Mokhles S; Nuyttens JJ; Maat AP; Birim Ö; Aerts JG; Bogers AJ; Takkenberg JJ
Ann Surg Oncol; 2015 Jan; 22(1):316-23. PubMed ID: 24962941
[TBL] [Abstract][Full Text] [Related]
15. Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer.
Guckenberger M; Klement RJ; Kestin LL; Hope AJ; Belderbos J; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Xiao Y; Grills IS
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1074-81. PubMed ID: 23154077
[TBL] [Abstract][Full Text] [Related]
16. Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: A propensity score matching analysis.
Matsuo Y; Chen F; Hamaji M; Kawaguchi A; Ueki N; Nagata Y; Sonobe M; Morita S; Date H; Hiraoka M
Eur J Cancer; 2014 Nov; 50(17):2932-8. PubMed ID: 25281527
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiotherapy in patients with stage I non-small-cell lung cancer aged 75 years and older: retrospective results from a multicenter consortium.
Samuels MA; Kandula S; Koru-Sengul T; Bogart JA; Salama JK; Aridgides PD; Gajra A; Lilenbaum RC
Clin Lung Cancer; 2013 Jul; 14(4):446-51. PubMed ID: 23660522
[TBL] [Abstract][Full Text] [Related]
18. Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy.
Yamamoto T; Kadoya N; Shirata Y; Koto M; Sato K; Matsushita H; Sugawara T; Umezawa R; Kubozono M; Ishikawa Y; Kozumi M; Takahashi N; Ito K; Katagiri Y; Takeda K; Jingu K
Radiat Oncol; 2015 Feb; 10():35. PubMed ID: 25886315
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?
Onishi H; Shirato H; Nagata Y; Hiraoka M; Fujino M; Gomi K; Karasawa K; Hayakawa K; Niibe Y; Takai Y; Kimura T; Takeda A; Ouchi A; Hareyama M; Kokubo M; Kozuka T; Arimoto T; Hara R; Itami J; Araki T
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1352-8. PubMed ID: 20638194
[TBL] [Abstract][Full Text] [Related]
20. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
Koshy M; Malik R; Weichselbaum RR; Sher DJ
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):344-50. PubMed ID: 25636759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
